BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 27449897)

  • 41. Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum.
    Kortagere S; Welsh WJ; Morrisey JM; Daly T; Ejigiri I; Sinnis P; Vaidya AB; Bergman LW
    J Chem Inf Model; 2010 May; 50(5):840-9. PubMed ID: 20426475
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of Novel Plasmodium falciparum Hexokinase Inhibitors with Antiparasitic Activity.
    Davis MI; Patrick SL; Blanding WM; Dwivedi V; Suryadi J; Golden JE; Coussens NP; Lee OW; Shen M; Boxer MB; Hall MD; Sharlow ER; Drew ME; Morris JC
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6023-33. PubMed ID: 27458230
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification and structure-activity relationship (SAR) studies of carvacrol derivatives as potential anti-malarial against Plasmodium falciparum falcipain-2 protease.
    Uddin A; Singh V; Irfan I; Mohammad T; Singh Hada R; Imtaiyaz Hassan M; Abid M; Singh S
    Bioorg Chem; 2020 Oct; 103():104142. PubMed ID: 32763521
    [TBL] [Abstract][Full Text] [Related]  

  • 44. On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity.
    Edgar RCS; Malcolm TR; Siddiqui G; Giannangelo C; Counihan NA; Challis M; Duffy S; Chowdhury M; Marfurt J; Dans M; Wirjanata G; Noviyanti R; Daware K; Suraweera CD; Price RN; Wittlin S; Avery VM; Drinkwater N; Charman SA; Creek DJ; de Koning-Ward TF; Scammells PJ; McGowan S
    mBio; 2024 Jun; 15(6):e0096624. PubMed ID: 38717141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In silico study of M18 aspartyl amino peptidase (M18AAP) of Plasmodium vivax as an antimalarial drug target.
    Rout S; Mahapatra RK
    Bioorg Med Chem; 2019 Jun; 27(12):2553-2571. PubMed ID: 30929948
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Yeast-based high-throughput screen identifies Plasmodium falciparum equilibrative nucleoside transporter 1 inhibitors that kill malaria parasites.
    Frame IJ; Deniskin R; Rinderspacher A; Katz F; Deng SX; Moir RD; Adjalley SH; Coburn-Flynn O; Fidock DA; Willis IM; Landry DW; Akabas MH
    ACS Chem Biol; 2015 Mar; 10(3):775-83. PubMed ID: 25602169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In-Silico molecular docking and simulation studies on novel chalcone and flavone hybrid derivatives with 1, 2, 3-triazole linkage as vital inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
    Thillainayagam M; Malathi K; Ramaiah S
    J Biomol Struct Dyn; 2018 Nov; 36(15):3993-4009. PubMed ID: 29132266
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Novel Fluorescence Resonance Energy Transfer-Based Screen in High-Throughput Format To Identify Inhibitors of Malarial and Human Glucose Transporters.
    Kraft TE; Heitmeier MR; Putanko M; Edwards RL; Ilagan MX; Payne MA; Autry JM; Thomas DD; Odom AR; Hruz PW
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7407-7414. PubMed ID: 27736766
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.
    Fogel GB; Cheung M; Pittman E; Hecht D
    J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of piperazine-based hydroxamic acid inhibitors against falcilysin, an essential malarial protease.
    Chance JP; Fejzic H; Hernandez O; Istvan ES; Andaya A; Maslov N; Aispuro R; Crisanto T; Nguyen H; Vidal B; Serrano W; Kuwahara B; Pugne Andanado C; Goldberg DE; Mallari JP
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1846-1848. PubMed ID: 29691139
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug target prioritization in Plasmodium falciparum through metabolic network analysis, and inhibitor designing using virtual screening and docking approach.
    Yadav MK; Pandey SK; Swati D
    J Bioinform Comput Biol; 2013 Aug; 11(4):1350003. PubMed ID: 23859267
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Computational Design of Novel Allosteric Inhibitors for
    Shehzad S; Pandey R; Malhotra P; Gupta D
    Molecules; 2021 May; 26(9):. PubMed ID: 34066964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-throughput screening for small-molecule inhibitors of plasmodium falciparum glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase.
    Preuss J; Hedrick M; Sergienko E; Pinkerton A; Mangravita-Novo A; Smith L; Marx C; Fischer E; Jortzik E; Rahlfs S; Becker K; Bode L
    J Biomol Screen; 2012 Jul; 17(6):738-51. PubMed ID: 22496096
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel inhibitors of the Plasmodium falciparum electron transport chain.
    Stocks PA; Barton V; Antoine T; Biagini GA; Ward SA; O'Neill PM
    Parasitology; 2014 Jan; 141(1):50-65. PubMed ID: 24401337
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.
    Deniskin R; Frame IJ; Sosa Y; Akabas MH
    Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In silico identification of inhibitors against Plasmodium falciparum histone deacetylase 1 (PfHDAC-1).
    Kumar A; Dhar SK; Subbarao N
    J Mol Model; 2018 Aug; 24(9):232. PubMed ID: 30109440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In silico Screening and Evaluation of Plasmodium falciparum Protein Kinase 5 (PK5) Inhibitors.
    Eubanks AL; Perkins MM; Sylvester K; Ganley JG; Posfai D; Sanschargrin PC; Hong J; Sliz P; Derbyshire ER
    ChemMedChem; 2018 Dec; 13(23):2479-2483. PubMed ID: 30328274
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Virtual screening as a tool to discover new β-haematin inhibitors with activity against malaria parasites.
    de Sousa ACC; Combrinck JM; Maepa K; Egan TJ
    Sci Rep; 2020 Feb; 10(1):3374. PubMed ID: 32099045
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of (4-(9H-fluoren-9-yl) piperazin-1-yl) methanone derivatives as falcipain 2 inhibitors active against Plasmodium falciparum cultures.
    Hernández-González JE; Salas-Sarduy E; Hernández Ramírez LF; Pascual MJ; Álvarez DE; Pabón A; Leite VBP; Pascutti PG; Valiente PA
    Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2911-2923. PubMed ID: 30253205
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysing the essential proteins set of Plasmodium falciparum PF3D7 for novel drug targets identification against malaria.
    Ali F; Wali H; Jan S; Zia A; Aslam M; Ahmad I; Afridi SG; Shams S; Khan A
    Malar J; 2021 Aug; 20(1):335. PubMed ID: 34344361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.